Panax notoginseng for Health & Longevity - Quick Reference Sheet

Panax notoginseng for Health & Longevity

Created on 06/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A ginseng-family root traditionally used to stop bleeding and move blood. The most consistent human evidence is for easing chest pain in heart disease and supporting recovery after a clot-type stroke as an add-on; longevity, bone, and brain claims rest on lab and animal work. The clearest concern is bleeding, especially with blood thinners or before surgery. (Full Review)

Protocol

Dose
200–600 mg daily
Standardized saponin (PNS) extract, the doses used in oral trials
Schedule
Split, twice daily with food
Improves tolerability and smooths exposure given variable saponin absorption
Form
Oral extract or powder
Traditional raw or steamed root powder ~1–3 g/day is an alternative approach
Time to effect
Angina & circulation
Weeks to a few months
Symptom and marker changes assessed over this window; no effect expected within days

Benefits

Contraindications
  • Bleeding disorders
  • Surgery within ~1 week (discontinue ≥7 days before elective surgery)
  • Pregnancy or breastfeeding
  • Warfarin or other anticoagulants without medical supervision
  • Significant liver or kidney impairment (e.g., Child-Pugh Class C)
  • Active gastrointestinal bleeding or recent hemorrhagic stroke
  • Platelet counts below the normal range
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, heparin, aspirin, clopidogrel)
  • NSAIDs (ibuprofen, naproxen, aspirin) and high-dose fish oil
  • Blood-thinning supplements (ginkgo, garlic, vitamin E, Panax ginseng, curcumin, nattokinase)
  • CYP3A4/P-glycoprotein substrates (certain statins, immunosuppressants such as cyclosporine and tacrolimus, some chemotherapy agents)
  • Antidiabetic drugs (metformin, sulfonylureas)

Risk & Side Effects

  • High: Increased bleeding risk; serious reactions to injectable preparations
  • Medium: Gastrointestinal upset
  • Low: Liver and kidney toxicity with prolonged high-dose use; allergic and skin reactions
  • Speculative: Hormonal and pregnancy-related effects

Monitoring

Marker Target Why
Complete blood count (platelets, hemoglobin) Platelets ~200–400 ×10⁹/L; hemoglobin sex-appropriate Detects bleeding-related changes and baseline platelet status
PT/INR and aPTT (clotting times) Within normal lab range unless anticoagulated Tracks the root's anticoagulant effect, especially with blood thinners
Lipid panel (LDL-C, total cholesterol, triglycerides) LDL-C <100 mg/dL (lower if high cardiovascular risk) Assesses the cardiovascular/lipid benefit signal
Fasting glucose / HbA1c Glucose 70–90 mg/dL; HbA1c <5.4% Monitors possible additive blood-sugar lowering
Liver enzymes (ALT, AST) ALT/AST roughly <25 U/L (functional) Screens for the rare liver toxicity seen in animal studies
Kidney function (eGFR, creatinine) eGFR >90 mL/min/1.73m²; creatinine sex-appropriate Screens for kidney toxicity and tracks diabetic-kidney benefit

Cadence: Baseline before starting, then ~4–8 weeks after starting, then every 6–12 months with chronic use; more frequent for anyone on interacting medications.

Qualitative Assessment

  • Frequency and severity of angina or chest discomfort (where relevant)
  • Easy bruising, prolonged bleeding, or unusual nosebleeds
  • Energy levels and exercise tolerance
  • General sense of circulation (cold hands/feet, recovery from minor injury)
  • Any gastrointestinal upset or skin reactions